CMS Pharmaceuticals announced that its innovative drug, Levoflan®, has obtained the new drug market approval application from the National Medical Products Administration of China (NMPA) on June 11, 2024, and received a drug registration certificate on June 18. The product is an oral diagnostic drug used to enhance the visualization of colonic lesions to assist in screening and monitoring adult patients undergoing colonoscopy. Levoflan® uses patented multi-matrix (MMX) technology to deliver active ingredients directly to the colon and control local release, thereby improving the detection rate of non-polypoid colonic lesions. The results of Phase III clinical trials in China showed that the product significantly improved lesion detection rates. Levoflan® was approved for marketing in the European Union under...Show More

CMS Pharmaceuticals announced that its innovative drug, Levoflan®, has obtained the new drug market approval application from the National Medical Products Administration of China (NMPA) on June 11, 2024, and received a drug registration certificate on June 18. The product is an oral diagnostic drug used to enhance the visualization of colonic lesions to assist in screening and monitoring adult patients undergoing colonoscopy. Levoflan® uses patented multi-matrix (MMX) technology to deliver active ingredients directly to the colon and control local release, thereby improving the detection rate of non-polypoid colonic lesions. The results of Phase III clinical trials in China showed that the product significantly improved lesion detection rates. Levoflan® was approved for marketing in the European Union under the name Lumeblue™ in 2020 and obtained exclusive licensing rights in December of the same year. With the popularization of colorectal cancer screening in China, the number of colonoscopy examinations is expected to increase significantly. CMS Pharmaceuticals will promote the commercialization of the product for the benefit of patients. Shareholders and investors are advised to exercise caution when trading.